FDA Approves Sotatercept, First-in-Class Treatment for Adults With PAH
Adults with pulmonary arterial hypertension (PAH) have a new treatment available with the FDA approval of sotatercept (Winrevair; Merck), an activin signaling inhibitor biologic.